AR083095A1 - Cocristal de aprepitant l-prolina y composicion farmaceutica - Google Patents
Cocristal de aprepitant l-prolina y composicion farmaceuticaInfo
- Publication number
- AR083095A1 AR083095A1 ARP110103486A AR083095A1 AR 083095 A1 AR083095 A1 AR 083095A1 AR P110103486 A ARP110103486 A AR P110103486A AR 083095 A1 AR083095 A1 AR 083095A1
- Authority
- AR
- Argentina
- Prior art keywords
- proline
- aprepitant
- crystal
- prolina
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se describen un cocristal de aprepitant L-prolina H2O 1:1:1, así como también las composiciones farmacéuticas que contienen el cocristal o la composición de aprepitant L-prolina H2O 1:1:1 y un portador farmacéuticamente aceptable. El cocristal o la composición de aprepitant L-prolina H2O 1:1:1 se pueden utilizar en la misma forma que el aprepitant para tratar o prevenir los trastornos relacionados con la emesis, una enfermedad neuropsiquiátrica, una enfermedad inflamatoria, el dolor, el cáncer, una enfermedad de la piel, picazón, una enfermedad respiratoria, o una adicción.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38574410P | 2010-09-23 | 2010-09-23 | |
| US201161439654P | 2011-02-04 | 2011-02-04 | |
| US201161498214P | 2011-06-17 | 2011-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083095A1 true AR083095A1 (es) | 2013-01-30 |
Family
ID=44907915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103486 AR083095A1 (es) | 2010-09-23 | 2011-09-23 | Cocristal de aprepitant l-prolina y composicion farmaceutica |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9029369B2 (es) |
| EP (1) | EP2618828B1 (es) |
| JP (1) | JP5997162B2 (es) |
| KR (1) | KR101833578B1 (es) |
| CN (1) | CN103221049B (es) |
| AR (1) | AR083095A1 (es) |
| AU (1) | AU2011306391B2 (es) |
| BR (1) | BR112013006651A2 (es) |
| CA (1) | CA2846460C (es) |
| ES (1) | ES2616752T3 (es) |
| HK (1) | HK1187554A1 (es) |
| IL (1) | IL225443A0 (es) |
| TW (1) | TWI540131B (es) |
| WO (1) | WO2012038937A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2618828B1 (en) | 2010-09-23 | 2016-11-23 | Nuformix Limited | Aprepitant l-proline composition and cocrystal |
| WO2013076659A1 (en) | 2011-11-25 | 2013-05-30 | Nuformix Limited | Aprepitant l-proline solvates - compositions and cocrystals |
| US10098859B2 (en) | 2012-09-05 | 2018-10-16 | Amri Ssci, Llc | Cocrystals of p-coumaric acid |
| US20160324881A1 (en) * | 2013-12-30 | 2016-11-10 | Oncoprevent Gmbh | Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer |
| CN112020506B (zh) | 2018-02-07 | 2024-10-11 | 里亚塔医药公司 | 新生霉素类似物与脯氨酸的共晶体形式 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US6048859A (en) | 1992-06-29 | 2000-04-11 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| US5719147A (en) | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| ZA985765B (en) | 1997-07-02 | 1999-08-04 | Merck & Co Inc | Polymorphic form of a tachykinin receptor antagonist. |
| EP1515703A1 (en) | 2002-06-21 | 2005-03-23 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
| CA2513746C (en) * | 2003-02-28 | 2012-08-28 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP2034952A4 (en) | 2006-06-16 | 2011-08-17 | Reddys Lab Ltd Dr | APREPITANT COMPOSITIONS |
| EP2254555A4 (en) * | 2008-02-27 | 2013-10-09 | Reddys Lab Ltd Dr | APREPITANT FORMS WITH INCREASED SOLUBILITY AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF |
| EP2618828B1 (en) | 2010-09-23 | 2016-11-23 | Nuformix Limited | Aprepitant l-proline composition and cocrystal |
-
2011
- 2011-09-23 EP EP11779217.6A patent/EP2618828B1/en active Active
- 2011-09-23 JP JP2013529758A patent/JP5997162B2/ja active Active
- 2011-09-23 TW TW100134362A patent/TWI540131B/zh active
- 2011-09-23 CN CN201180055997.5A patent/CN103221049B/zh active Active
- 2011-09-23 KR KR1020137010228A patent/KR101833578B1/ko active IP Right Grant
- 2011-09-23 WO PCT/IB2011/054210 patent/WO2012038937A1/en active Application Filing
- 2011-09-23 CA CA2846460A patent/CA2846460C/en active Active
- 2011-09-23 AR ARP110103486 patent/AR083095A1/es unknown
- 2011-09-23 US US13/825,380 patent/US9029369B2/en active Active
- 2011-09-23 BR BR112013006651A patent/BR112013006651A2/pt not_active Application Discontinuation
- 2011-09-23 AU AU2011306391A patent/AU2011306391B2/en active Active
- 2011-09-23 ES ES11779217.6T patent/ES2616752T3/es active Active
-
2013
- 2013-03-21 IL IL225443A patent/IL225443A0/en active IP Right Grant
-
2014
- 2014-01-23 HK HK14100748.9A patent/HK1187554A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201217366A (en) | 2012-05-01 |
| CN103221049A (zh) | 2013-07-24 |
| EP2618828B1 (en) | 2016-11-23 |
| EP2618828A1 (en) | 2013-07-31 |
| KR20140040671A (ko) | 2014-04-03 |
| JP2013537901A (ja) | 2013-10-07 |
| US9029369B2 (en) | 2015-05-12 |
| HK1187554A1 (zh) | 2014-04-11 |
| KR101833578B1 (ko) | 2018-02-28 |
| CA2846460A1 (en) | 2012-03-29 |
| AU2011306391B2 (en) | 2016-12-15 |
| BR112013006651A2 (pt) | 2017-07-18 |
| CN103221049B (zh) | 2015-11-25 |
| IL225443A0 (en) | 2013-06-27 |
| TWI540131B (zh) | 2016-07-01 |
| WO2012038937A1 (en) | 2012-03-29 |
| CA2846460C (en) | 2019-01-08 |
| US20130252949A1 (en) | 2013-09-26 |
| ES2616752T3 (es) | 2017-06-14 |
| AU2011306391A1 (en) | 2013-04-11 |
| JP5997162B2 (ja) | 2016-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| DOP2013000104A (es) | Antagonistas de mdm2 de espiro-oxindol | |
| CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| BR112012011317A2 (pt) | antagonistas espiro-oxindóis de mdm2 | |
| PE20150092A1 (es) | Composiciones farmaceuticas que contienen fumarato de dimetilo | |
| BR112015020389A8 (pt) | compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos | |
| CL2014001158A1 (es) | Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros. | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| BR112012023021A2 (pt) | compostos de indazol e seus usos | |
| CL2010001348A1 (es) | Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad. | |
| CR20190073A (es) | FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265) | |
| EA201291310A1 (ru) | Композиция ингибитора jak для местного применения | |
| UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
| SV2011003901A (es) | Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif | |
| UY35293A (es) | Isotiazoles sustituidos con amino | |
| BR112013028534A2 (pt) | compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos | |
| CO6640327A2 (es) | Compuestos de pirazol como inhibidores del receptor sigma | |
| ECSP15013883A (es) | Benzamidas | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
| CL2017000845A1 (es) | Inhibidores de gingipaina de lisina | |
| CO2019008053A2 (es) | Agente terapéutico para enfermedades del hígado | |
| AR083095A1 (es) | Cocristal de aprepitant l-prolina y composicion farmaceutica | |
| MX2016000294A (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| CO6280488A2 (es) | Combinacion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |